Objectives The aim of this study was to obtain a valid estimate of the clinical effects of primary percutaneous coronary intervention (PPCI) in relation to age.
Despite the dominant role of age in the prognosis of coronary artery disease (CAD), elderly patients are often excluded from participation in clinical trials evaluating efficacy and safety of cardiac treatment (1) . The main reason why is that clinical trialists tend to favor the enrollment of patients at low risk of potential side effects, and large proportions of elderly patients meet 1 or more of the associated exclusion criteria.
Because of the limited availability of clinical trial data and the increasing variability in treatment response in relation to age, estimates of treatment effect in elderly CAD patients seem to be uncertain for a broad variety of clinical situations. Particularly, uncertainty exists about the balance between beneficial and harmful treatment effects, which hampers the application of evidence-based treatment in clinical practice. For example, the application of reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction (MI) is strongly related to age: elderly patients less often receive reperfusion therapy than their younger counterparts (2) (3) (4) . Most likely the choice for conservative treatment in elderly persons is based on negative perceptions of the chances to reduce mortality risk due to limitation of the infarct size (treatment benefit) relative to the chances to cause harm. Particularly, the risk of severe disability or even death due to severe hemorrhagic complications is feared in elderly patients receiving fibrinolytic (FL) therapy. Still, the underuse of reperfusion therapy in older MI patients is also reported with respect to primary percutaneous coronary intervention (PPCI) (5) . Apparently, in clinical practice, there is a mismatch between (suspected) patient risk and applied treatment. This treatment-risk paradox has been observed in other settings in clinical cardiology as well (6, 7) .
The clinical outcome after PPCI as compared with FL in elderly patients has been evaluated in the randomized trial of de Boer et al. (8) (patients age 75ϩ years) and in the randomized SENIOR PAMI (Senior Primary Angioplasty in Myocardial Infarction) trial (patients age 70ϩ years) (9). Although de Boer et al. (8) demonstrated a favorable clinical outcome after PPCI-a statistically significant reduction was observed in the 30-day incidence of death, repeat myocardial infarction (reMI), and stroke-the sample sizes of both trials were too small to draw definite conclusions. We recently pooled individual patient data from 22 clinical trials of PPCI versus FL in patients with acute MI. This meta-analytic dataset provides a unique and powerful opportunity to study the clinical outcome of PPCI in relation to age.
Methods
Details on the applied methodology of the pooled analysis have been published previously (10) . In this section, we briefly describe the trial selection and data collection process, end point definition, and data analysis for the current study. Trial selection. All randomized trials that enrolled at least 50 patients presenting with MI assigned to treatment with FL or PPCI were considered. Trials published between January 1990 and December 2002 were identified by OVID MEDLINE and ISI Web science with a broad range of key words. Each trial identified in this search was evaluated for patient population, study treatment, protocol, and end points. The primary investigators of these studies were contacted for verification and access to the individual patient data. In this way, 25 eligible trials were identified, which enrolled a total of 7,743 patients. Individual patient data were unavailable in 2 smaller trials (140 patients) (11, 12) , whereas the investigators of the larger CAPTIM (Comparison of Angioplasty and Prehospital Thrombolysis in acute Myocardial Infarction) trial (n ϭ 840) elected not to release their data (13) . Consequently, individual patient data from 22 trials (n ϭ 6,763) were pooled for the primary analysis. Table 1 presents the main design features of the included trials (8,14 -34) . Data were assessed for completeness and internal consistency with published reports. Any discrepancies between analysis of the data provided and previously published results were queried and resolved with the primary investigator.
Definitions of clinical end points.
The primary end point of this pooled analysis was all-cause mortality at 30 days after randomization. Secondary end points included reMI and stroke as well as the composite end points all-cause mortality or reMI and all-cause mortality, reMI, or stroke. End points were counted until 30 days after randomization. Statistical analysis. Summary statistics for all continuous variables are presented as medians with the corresponding interquartile range, and discrete variables are presented as counts and percentages. Patients were categorized according to their age into 5 categories: Յ50, Ͼ50 to 60, Ͼ60 to 70, Ͼ70 to 80, and Ͼ80 years. Differences in baseline characteristics in relation to age were evaluated by Kruskal-Wallis tests or Mantel-Haenszel chi-square tests for trend, as appropriate.
All analyses of the relation between randomized treatment and the incidence of clinical end points were performed according to the intention-to-treat principle. Age-specific outcome data were pooled with the Cochrane-Mantel-Haenszel method, and odds ratios (OR) and 95% confidence intervals (CI) for clinical end points are reported. Breslow-Day tests were applied to examine statistical evidence of heterogeneity among the age-specific ORs. The association between treatment and the clinical end points in relation to age were also evaluated by logistic regression. First, crude ORs for study end points were determined on the basis of the single fixed effect logistic regression model, stratified by age-category. Subsequently, nonstratified models were fitted with age (as a continuous variable), treatment, and the age ϫ treatment interaction term. To adjust for trial effects and for variations in the standards of practice across participating institutions, these models were then extended, taking study membership into account. The final multivariable adjustment included study membership, sex, body weight, diabetes mellitus, previous MI, prior revascularization, anterior MI at presentation, heart rate, systolic blood pressure, and time to treatment.
Time to treatment was categorized into time from symptom onset to randomization ("presentation delay") and time from randomization to treatment ("treatment delay"). Per definition, the interval between randomization and the actual commencement of treatment is a post-randomization variable, which is influenced by allocated treatment. Hence, analyses in relation to treatment delay that are based on observations in individual patients can result in biased estimates of treatment effect. Moreover, patients are randomized to either FL or PPCI; so on a patient-level, time to treatment can only be obtained for 1 strategy. Analyses based on observations on hospital level might help to overcome this. Thus, the median time between randomization and the start of treatment (i.e., first injection of the fibrinolytic agent or the first balloon inflation) was calculated for each of the 153 participating hospitals. The hospital-specific difference between these median times was then determined, which is hereafter referred to as "PCIrelated delay," and assigned to each patient within that hospital. Consequently, PCI-related delay should be inter- 
Results
Patients. This pooled analysis included 6,763 patients from 22 trials in which patients were randomized to FL (n ϭ 3,383) or PPCI (n ϭ 3,380). There were important differences in clinical baseline characteristics in relation to age ( Table 2) . Elderly patients had an unfavorable risk profile, because they more often had diabetes mellitus, a history of MI, and a longer presentation delay. For example, 46% of patients in the Յ50 years-age category were randomized within 2 h after the onset of symptoms, in contrast to only 26% in those older than 80 years of age. Interestingly, PCI-related delay tended to decrease with age. We observed a statistically significant relation among admission systolic blood pressure, heart rate, and age, but the difference in median values of these hemodynamic parameters between younger and elderly patients seemed clinically irrelevant. Clinical end points. Overall, 446 (6.6%) patients died within 30 days of randomization. Mortality was significantly lower in patients randomized to PPCI (n ϭ 178; 5.3%) than in patients randomized to FL (n ϭ 268; 7.9%). Elderly patients had higher mortality risk than younger patients, irrespective of treatment (Table 3) . Primary PCI was associated with a lower incidence of death than FL therapy in all age-categories, except in patients Յ50 years of age (Table 3 , Fig. 1 ). The Breslow-Day test for homogeneity of ORs across age-categories was nonsignificant (p ϭ 0.24), and interaction between age and treatment was not statistically significant (p ϭ 0.73). Hence, there was no evidence that the observed mortality reduction by PPCI was heterogeneous with respect to age. After multivariable adjustment, PPCI was associated with a 36% proportional reduction in the odds of death compared with FL therapy, irrespective of age (adjusted OR: 0.65; 95% CI: 0.52 to 0.79).
Repeat MI occurred in 225 (6.7%) patients who were randomized to FL and in 80 (2.4%) of those randomized to PPCI. A lower incidence of reMI in patients randomized to PPCI was consistently seen in all age-categories ( Table 3 , Fig. 1 ), and there was no evidence of heterogeneity in ORs (p ϭ 0.67). Primary PCI was associated with a 63% proportional reduction in the odds of reMI (adjusted OR: 0.37; 95% CI: 0.28 to 0.48) and a 49% reduction in the composite end point of all-cause mortality or reMI (adjusted OR: 0.51; 95% CI: 0.43 to 0.60), irrespective of age.
Similar results were observed with respect to stroke, which occurred in 83 (2.6%) of the patients randomized to FL and in 48 (1.5%) of those randomized to PPCI. Although the incidence of stroke was increased after PPCI in patients younger than 50 years of age (Fig. 1C) , the CI of treatment effect was wide, and there was no evidence of heterogeneity in ORs in relation to age (p ϭ 0.40). Primary PCI was systematically associated with a lower incidence of the composite end point of all-cause mortality, reMI, or stroke in all age-categories, and again there was no evidence of heterogeneity in ORs (p ϭ 0.35). Absolute treatment effects. Figure 2 shows 30-day mortality in patients randomized to PPCI and FL (panel A) as well as the absolute mortality reduction by PPCI (panel B) in relation to age as a continuous variable. Apparently, the absolute risk reduction was strongly and positively associated with age. For example, at age 60 years, PPCI was associated with 1.4 fewer deaths/100 patients treated compared with FL, whereas the risk reduction amounted to 5.1/100 patients at age 80 years. Octogenarians. Octogenarians (Ͼ80 years of age) comprise a clinically relevant cohort and represented 6% of patients. In this cohort, the patients who were randomized to PPCI had a lower incidence of mortality (26.4% vs. 18.3% events; p ϭ 0.049), reMI (7.0% vs. 3.9%; p ϭ 0.18), and stroke (7.9% vs. 5.8%; p ϭ 0.45) than their counterparts who were randomized to FL. Statistical significance was not reached for each of these end points, most likely due to small numbers.
Discussion
In this pooled analysis, which was based on randomized trials that involved 6,763 MI patients, age did not modify the mortality reduction by PPCI compared with FL therapy. Because age is a key determinant of mortality in MI patients, the consequence of the consistent relative risk reduction across all age groups is an increasing absolute risk reduction with increasing age and a decreasing number of patients that need to undergo PPCI (instead of FL therapy) to prevent 1 death-the "number needed to treat". Noteworthy, PPCI was associated with significantly reduced mortality in patients age 80 years or over. The estimated number needed to treat in these patients was only 20. In view of our results, age per se should not be considered an exclusion criterion for the application of PPCI. One of the most severe complications of FL therapy is the risk of stroke, particularly intracranial hemorrhage (ICH). This complication occurs in approximately 1% of patients receiving FL therapy, with a case-fatality of around 50%, whereas one-half of the ICH victims who survive will remain irreversibly disabled (35) . Because age is 1 of the strongest determinants of ICH risk after pharmacologybased reperfusion therapy (36) , physicians tend to be quite conservative in treating elderly persons. Indeed, in our data, among octogenarians who received FL, stroke risk was as high as 8%. We demonstrated that PPCI was associated with a reduced incidence of stroke. Importantly, the risk reduction was particularly strong in elderly patients (although there was no evidence of heterogeneity in relative stroke reduction in relation to age). This observation provides another argument to not systematically exclude elderly patients from treatment with PPCI. We did not observe significant heterogeneity in treatment effect with respect to the specified outcome events. Indeed, the CIs around the point estimates of treatment effect in the 5 age-categories were largely overlapping. Still, any heterogeneity cannot be excluded with complete certainty. Despite the considerable amount of included patients, the applied statistical tests of heterogeneity lacked power to reveal small but clinically relevant differences. The true existence of such differences is unlikely as far as death is concerned, because point estimates were quite consistent across age-groups. However, we acknowledge that age might be a modifier of the influence of PPCI on the incidence of reMI (risk reduction slightly decreases with age) and stroke (risk reduction slightly increases with age). In fact, additional randomized trials are needed to obtain more precise estimates of treatment effects in strata according to age, but in view of the unambiguous results of the trials that have been conducted, it is unlikely that such new trials will ever be conducted.
We realize that elderly patients who are eligible to participate in a randomized trial might not be representative for real-world patients. Because elderly persons do not fit the inclusion and exclusion criteria as younger patients, they are more likely to be excluded from participation in trials. Indeed, not only do elderly patients often suffer from comorbidities that formally exclude participation in most trials-such as dementia, gastrointestinal bleeds, or malignancy-but clinicians also are often reluctant to include the fragile elderly patient who otherwise doesn't meet exclusion criteria. Thus, elderly persons who are included in trials form a selected group, more so than younger patients. Consequently, the observed favorable effects in elderly persons probably will not fully be extrapolated to the general population. We cannot overcome this issue in the context of our pooled analysis.
The main strength of this study is that it is based on randomized trials. Thus, although one might challenge the external validity, the observed results are at least internally valid (i.e., the results are valid for the type of patients that have entered the included trials). In this respect, the main limitation of our analyses is that the CAPTIM trial data were not included. The CAPTIM trial strongly suggested that the strategy of (pre-hospital) FL, followed by a "rescue" PCI in case of persistent ischemia, might result in a mortality reduction compared with the PPCI strategy in patients presenting within 2 h after onset of symptoms. Although these results were not confirmed in the PCAT-2 N T I O N S , V O L . 3 , N O . 3 , 2 0 1 0 de Boer et al. H 2 0 1 0 : 3 2 4 -3 1 (The Primary Coronary Angioplasty vs. Thrombolysis-2) main analysis (in fact, a statistically significant mortality reduction was observed in favor of PPCI in patients presenting within 2 h) (10), the inclusion of the CAPTIM data would have led to more precise estimates of treatment effect in patients presenting early. This particularly affected younger patients, because they tend to present earlier than elderly persons.
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Conclusions
In this pooled analysis of randomized clinical trials, there was no evidence that the reduction in clinical end points by PPCI was influenced by age. Hence, age per se should not be considered an exclusion criterion for the application of PPCI.
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